- Home
- THG vs RYTM Comparison
THG vs RYTM Comparison
Compare THG & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | THG | RYTM |
|---|---|---|
| Founded | 1852 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.4B |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | THG | RYTM |
|---|---|---|
| Price | $174.46 | $92.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $198.00 | $129.43 |
| AVG Volume (30 Days) | 201.7K | ★ 715.6K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | ★ 55.21 | 28.34 |
| EPS | ★ 18.16 | N/A |
| Revenue | ★ $6,594,400,000.00 | N/A |
| Revenue This Year | $3.04 | $57.46 |
| Revenue Next Year | $4.24 | $85.60 |
| P/E Ratio | $9.61 | ★ N/A |
| Revenue Growth | ★ 5.72 | N/A |
| 52 Week Low | $147.76 | $45.91 |
| 52 Week High | $188.18 | $122.20 |
Technical Indicators
Market Signals| Indicator | THG | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 44.19 | 43.44 |
| Support Level | $173.68 | $85.59 |
| Resistance Level | $180.14 | $96.92 |
| Average True Range (ATR) | 3.38 | 4.54 |
| MACD | -0.38 | -0.12 |
| Stochastic Oscillator | 19.14 | 38.25 |
Price Performance
Historical ComparisonAbout THG Hanover Insurance Group Inc
The Hanover Insurance Group Inc is a holding company whose primary business is offering property and casualty insurance products and services. The company markets itself through independent agents and brokers in the United States while conducting business through Hanover Insurance, Citizens and other THG subsidiaries. The company conducts business operations through four operating segments: Core Commercial, Specialty, Personal Lines, and Other. The company operates an investment portfolio that is exposed to fixed-income securities.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.